TYK2 and prostate carcinoma: A recent Mendelian randomization (MR) study observed positive associations of a TYK2 loss-of-function mutation that mimic TYK2 inhibition with increased risk of lung cancer, non-Hodgkin lymphoma, and possibly prostate cancer.9